Table 1. Published selected trials in Ph... | American Society of Hematology

Table 1.

Published selected trials in Ph+ ALL

Study	N	Age, y, median [range]	Regimen	CMR rate	AlloHCT rate	RFS rate	OS rate
Imatinib
Lee et al³⁵	87	41 [16-71]	Intensive chemotherapy	66% (at remission)	68%	39% (5 y)	33% (5 y)
Yanada et al³⁶	80	48 [15-63]	Intensive chemotherapy	50% (day 63)	49%	—	76% (1 y)
Vignetti et al¹⁸	29	69 [61-83]	Corticosteroids	4%	—	48% (1 y)	74% (1 y)
Bassan et al³⁷	59	45 [20-66]	Intensive chemotherapy	—	72%	39% (5 y)	38% (5 y)
Fielding et al²	169	42 [16-64]	Intensive chemotherapy	—	72%	50% (4 y)	38% (4 y)
Daver et al⁵	54	51 [17-84]	Intensive chemotherapy	45% (overall)	30%	43% (5 y)	43% (5 y)
Chalandon et al²¹	133	45 [21-59]	Intensive chemotherapy	23% (2 cycles)	65%	—	46% (5 y)*
Chalandon et al²¹	135	49 [18-59]	Low-intensity chemotherapy	29% (2 cycles)	62%	—	46% (5 y)*
Wetzler et al³³	34	45 [24-57]	Intensive chemotherapy	—	44%	46% (5 y)	51% (5 y)
Dasatinib
Foà et al¹⁹	53	54 [24-77]	Corticosteroids	15% (day 85)	42%	22% (20 mo)	31% (20 mo)
Ravandi et al⁶	72	55 [21-80]	Intensive chemotherapy	65% (overall)	17%	44% (5 y)	46%(5 y)
Ravandi et al¹⁵	97	44 [20-60]	Intensive chemotherapy	—	42%	62% (3 y)	69% (3 y)
Rousselot et al²⁰	71	69 [55-83]	Low-intensity chemotherapy	24% (consolidation)	10%	28% (5 y)	36%(5 y)
Nilotinib
Kim et al¹⁴	90	47 [17-71]	Intensive chemotherapy	77% (3 mo)	63%	72% (2 y)	72% (2 y)
Ponatinib
Jabbour et al²⁸	37	51 [27-75]	Intensive chemotherapy	78% (overall)	24%	—	80% (2 y)

Study	N	Age, y, median [range]	Regimen	CMR rate	AlloHCT rate	RFS rate	OS rate
Imatinib
Lee et al³⁵	87	41 [16-71]	Intensive chemotherapy	66% (at remission)	68%	39% (5 y)	33% (5 y)
Yanada et al³⁶	80	48 [15-63]	Intensive chemotherapy	50% (day 63)	49%	—	76% (1 y)
Vignetti et al¹⁸	29	69 [61-83]	Corticosteroids	4%	—	48% (1 y)	74% (1 y)
Bassan et al³⁷	59	45 [20-66]	Intensive chemotherapy	—	72%	39% (5 y)	38% (5 y)
Fielding et al²	169	42 [16-64]	Intensive chemotherapy	—	72%	50% (4 y)	38% (4 y)
Daver et al⁵	54	51 [17-84]	Intensive chemotherapy	45% (overall)	30%	43% (5 y)	43% (5 y)
Chalandon et al²¹	133	45 [21-59]	Intensive chemotherapy	23% (2 cycles)	65%	—	46% (5 y)*
Chalandon et al²¹	135	49 [18-59]	Low-intensity chemotherapy	29% (2 cycles)	62%	—	46% (5 y)*
Wetzler et al³³	34	45 [24-57]	Intensive chemotherapy	—	44%	46% (5 y)	51% (5 y)
Dasatinib
Foà et al¹⁹	53	54 [24-77]	Corticosteroids	15% (day 85)	42%	22% (20 mo)	31% (20 mo)
Ravandi et al⁶	72	55 [21-80]	Intensive chemotherapy	65% (overall)	17%	44% (5 y)	46%(5 y)
Ravandi et al¹⁵	97	44 [20-60]	Intensive chemotherapy	—	42%	62% (3 y)	69% (3 y)
Rousselot et al²⁰	71	69 [55-83]	Low-intensity chemotherapy	24% (consolidation)	10%	28% (5 y)	36%(5 y)
Nilotinib
Kim et al¹⁴	90	47 [17-71]	Intensive chemotherapy	77% (3 mo)	63%	72% (2 y)	72% (2 y)
Ponatinib
Jabbour et al²⁸	37	51 [27-75]	Intensive chemotherapy	78% (overall)	24%	—	80% (2 y)

Pooled data.